NDAORAL-21TABLETPriority Review
Approved
May 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO TRI-CYCLEN 21 is an oral combined hormonal contraceptive containing ethinyl estradiol and norgestimate in a triphasic 21-day dosing regimen. It prevents ovulation and alters cervical mucus to provide contraceptive efficacy. This product serves as a standard-of-care option in the oral contraceptive market.
LOE Approaching
With LOE approaching and competitive pressure at 30%, expect defensive commercial strategies and potential team restructuring or redeployment to growth assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO TRI-CYCLEN 21 offers stable, mature-market experience in brand management and contraceptive marketing, but carries career risk due to LOE approaching and minimal linked job openings. Professionals should view this role as a platform to transition into growth-stage reproductive health or women's health initiatives.
Brand ManagerRegional Sales Manager
Worked on ORTHO TRI-CYCLEN 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.